that arrhythmologists could take a break again. However, the stabilization of the field was once again an illusion, as new studies such as the report by Borleffs et al. 3 send us in new directions. The question is:
now that the defibrillator is in place, what else can we do for our patients to improve their quality of life and survival? Borleff et al. analysed which baseline variables in patients receiving a defibrillator for secondary prevention are predictive of recurrent life-threatening ventricular arrhythmias and mortality. The main independent predictors were atrial fibrillation (AF), wide QRS, ejection fraction, and VT as a presenting arrhythmia. Theoretically, these four predictors can be modified at the moment of ICD implantation, and therefore there is plenty of scope for research to demonstrate that taking the necessary steps to do so will further benefit patients in the long run.
The obvious and already proven benefit is to implant a CRT in Class III-IV patients with a wide QRS. 2 However, in the near future, new data will be available from studies of patients in Class II. The INCIDENCE and MADIT III 4 studies are analysing secondary and primary prevention patients, respectively, and may clarify whether better results are obtained from implanting a CRT, rather than conventional ICD devices, in Class II patients with a wide QRS and severe left ventricular dysfunction.
The results of the REVERSE trial demonstrated that implanting a CRT at an early stage of the disease (Class I and II) induces reverse remodelling, without definitively establishing any functional benefit. 5 Although several small studies have found potential for CRT in patients with a narrow QRS, until now this has not been proven in a large randomized study. The potential benefit of CRT in patients with a narrow QRS is being explored by the ECHO-CRT trial, 6 which is recruiting patients with severe systolic dysfunction and dyssynchrony, proven by echocardiographic criteria. The aim is to establish whether patients with a narrow QRS could also benefit from CRT therapy. AF is mentioned in Borleffs et al. as the most powerful predictor of life-threatening arrhythmias and death. Despite its association with increased mortality, for many years AF was thought merely to represent a marker of more severe disease, rather than being a cause itself of increased mortality. More recently, epidemiological studies 7 have firmly established the link between increased mortality and AF, after adjusting for relevant covariates such as age, heart disease, etc. Therefore, there is an increasing awareness of the independent negative prognostic value of AF in several clinical situations. For example, AF is independently associated with increased mortality in primary prevention ICD trials 8 and in patients with heart failure, even when treated with CRT. 9 What are the possible mechanisms that link AF and mortality? On one hand is the worsening of heart failure. Fast, irregular ventricular rhythm and loss of atrial contraction certainly will decrease cardiac output and precipitate heart failure. Furthermore, chronic fast rhythm induces the so-called 'tachycardiomyopathy' with ventricular dilatation and remodelling, mimicking dilated cardiomyopathy. The study by Borleffs et al. 3 suggests another interesting hypothesis. In that study, AF was a predictor of appropriate shocks, suggesting that AF plays an important role in inducing ventricular arrhythmias. In fact, several case reports and studies have shown that a fast irregular ventricular rhythm induces ventricular arrhythmias. Therefore, whether through worsening the ventricular remodelling to cause heart failure or by provoking ventricular tachycardia, AF may increase mortality. On the other hand, AF ablation has proven effective in suppressing AF and improving ventricular function in selected patients, 10 and, therefore, in theory, may offer an opportunity for improvement in such patients. Both the AMICA trial 11 and that described in Natale et al. 12 are attempting to demonstrate a benefit of AF ablation in patients who receive an ICD for primary and secondary prevention or for depressed left ventricular ejection fraction. Finally, Borleffs et al. 3 identify VT at baseline as an independent predictor. It is well known that patients with VT have more severe LV dysfunction than patients presenting with ventricular fibrillation. On the other hand, patients with VT tend to suffer more recurrences than do those presenting with ventricular fibrillation (VF). Therefore, the negative effect of VT on prognosis could be related to a worse baseline profile, but also to a higher number of shocks. In fact, several studies have proven that patients suffering shocks have a worse prognosis, although no casual relationship has been clearly established so far. 13 Repeated VT episodes or shock may have an additive negative effect. On the other hand, ICD shocks (whether appropriate or not) have a negative impact on quality of life. Therefore, any step towards decreasing the number of arrhythmic episodes (ventricular or supraventricular) may in theory have a positive impact on the course of the disease. The recent SMASH VT study 14 has shown that prophylactic VT substrate ablation decreases the number of ICD therapies during follow-up. As a result, perhaps in the near future prophylactic ablation therapy at the time of implantation will be promoted. Other trials are in progress, attempting to demonstrate this hypothesis. 15 In summary, there are several actions, such as CRT, AF ablation, or VT ablation, that may improve the quality of life and prognosis in patients receiving an ICD for secondary prevention. The results of several ongoing trials may shed more light on the road ahead.
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